Claim Details

View detailed information about this claim and its related sources.

Back to Claims

Claim Information

Complete details about this extracted claim.

Claim Text
Dr. Charles Rudin, who studies this class of drugs at Memorial Sloan Kettering Cancer Center, noted that we wouldn’t necessarily know whether the approach the agents selected was the best, since no other drugs going after this target have been tested in a clinical trial.
Simplified Text
Dr. Charles Rudin stated that no other drugs targeting the same mechanism have been tested in a clinical trial.
Confidence Score
1.000
Claim Maker
Dr. Charles Rudin
Context Type
News Article
Context Details
{
    "person": "Dr. Charles Rudin",
    "organization": "Memorial Sloan Kettering Cancer Center"
}
Subject Tags
Health Research Medicine
UUID
1ae757d9-7893-4af9-9110-040a4a134ab0
Vector Index
✗ No vector
Created
September 18, 2026 at 7:09 PM (3 weeks ago)
Last Updated
September 18, 2026 at 7:09 PM (3 weeks ago)

Original Sources for this Claim (1)

All source submissions that originally contained this claim.

Screenshot of https://nytimes.com/2026/09/17/well/ai-drug-discovery-stanford.html
A.I. Agents as ‘Co-Scientists’? This Lab Says They Could Speed Drug Research.
Completed News
19 claims 🔥
3 weeks ago
https://nytimes.com/2026/09/17/well/ai-drug-discovery-stanford.html

Researchers at Stanford University are developing A.I. "co-scientists" to rapidly accelerate drug discovery by independently generating hypotheses and running computer-based experiments. This approach has already shown promising results in Covid-19 vaccine redesign and lung cancer drug target identification.

Artificial Intelligence Drug Discovery Biomedical Research Stanford University COVID-19 Cancer Research Machine Learning

Similar Claims (5)

Other claims identified as semantically similar to this one.